drugset / Trial / NCT03487848

Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection

NCT03487848

Phase 2 Terminated 5 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate daclatasvir in combination with sofosbuvir given to children with chronic hepatitis C infection

Timeline

Start
2018-06-25
Primary completion
2018-10-18
Completion
2020-09-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Daclatasvir Small molecule
Subject Sofosbuvir Small molecule